Manuka Honey in Second- and Grafted Third-degree Burns

Overview

Treatment strategies of II. degree burn wounds and split-skin grafted III. degree burn wounds aim at reducing infection and improving reepithelialization. The aim of this study is to evaluate time to reepithelialization, pain, microbiology and handling of manuka honey dressings with second-degree burn wounds and split-skin grafted burn wounds.

Full Title of Study: “Clinical Application Observation of Manuka Honey in Second- and Grafted Third-degree Burns”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2020

Detailed Description

In plastic and reconstructive surgery, treatment strategies of second-degree burn wounds and split-skin grafted third-degree burn wounds aim at reducing infection and improving reepithelialization. Although previous studies indicate that burn patients benefit from wound dressings containing manuka honey, only a few studies can be found. Therefore, the aim of this study is to evaluate time to reepithelialization, pain, microbiology and handling of manuka honey dressings with second-degree burn wounds and split-skin grafted burn wounds.

Interventions

  • Other: wound dressing
    • Manuka honey wound dressing

Arms, Groups and Cohorts

  • Experimental: Burn with or without split-skin graft
    • Second degree burns and third degree burns with split-skin graft that need wound dressings

Clinical Trial Outcome Measures

Primary Measures

  • Epithelialization
    • Time Frame: Up to 1 year
    • Rate of Epithelialization in percent

Secondary Measures

  • Pain
    • Time Frame: Up to 1 year
    • Visual analog scale (VAS)
  • Microbiology
    • Time Frame: Up to 1 year
    • Microbiological smear is assessed by gram+, gram- or no bacterium
  • Handling
    • Time Frame: Up to 1 year
    • Scale (0-4)

Participating in This Clinical Trial

Inclusion Criteria

  • Consent-capable male and female patients (or guardian) – ≥18 years of age – ability to asses pain Exclusion Criteria:

  • Immunosuppressive Therapy – Clinical wound infection – Allergy against honey – Relationship to someone who is involved in the study design or assessment – Participation in other clinical trials

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital Schleswig-Holstein
  • Collaborator
    • University of Luebeck
  • Provider of Information About this Clinical Study
    • Principal Investigator: Tobias Kisch, MD – University Hospital Schleswig-Holstein
  • Overall Official(s)
    • Tobias Kisch, MD, Principal Investigator, University of Lübeck, University Hospital Schleswig-Holstein
  • Overall Contact(s)
    • Tobias Kisch, MD, 00494515000, tobias.kisch@uksh.de

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.